Edition:
India

Sawai Pharmaceutical Co Ltd (4555.T)

4555.T on Tokyo Stock Exchange

5,000JPY
11:30am IST
Change (% chg)

¥50 (+1.01%)
Prev Close
¥4,950
Open
¥4,950
Day's High
¥5,010
Day's Low
¥4,950
Volume
232,200
Avg. Vol
437,792
52-wk High
¥6,700
52-wk Low
¥4,950

Chart for

About

SAWAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in the manufacture and sale of ethical drugs and proprietary drugs. The Company primarily provides central nerve system drugs, circulatory drugs, alimentary canal drugs, vitamin drugs, blood and body fluid drugs, metabolic medicinal... (more)

Overall

Beta: 0.46
Market Cap(Mil.): ¥247,727.09
Shares Outstanding(Mil.): 38.17
Dividend: 65.00
Yield (%): 2.00

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Sawai Pharmaceutical completes sale of 20 pct stake in Upsher-Smith Laboratories

* Says 20 percent stake in Upsher-Smith Laboratories LLC, which was wholly owned by co's unit SAWAI AMERICA, LLC, has been transferred to SUMITOMO CORP's wholly owned US-based unit Sumitomo Corporation of Americas, on Jan. 3

04 Jan 2018

BRIEF- Sawai Pharmaceutical to issue new shares and to distribute treasury common stock

* Says it plans to issue 5 million new shares and to distribute 1 million shares of its treasury common stock through public offering

27 Nov 2017

REFILE-TABLE-Sawai Pharmaceutical- 6-MTH group results

(Adds company forecast. Accounting policy for forecast is IFRS) Nov 13 (Reuters)- Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Sep 30, 2017 Sep 30, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 70.76 65.42

13 Nov 2017

BRIEF-Sawai Pharmaceutical to sell 20 pct stake in SAWAI AMERICA for $211 mln

* Says it plans to sell 20 percent stake in a wholly owned U.S.-based unit SAWAI AMERICA INC to Sumitomo Corporation of Americas, a wholly owned unit of SUMITOMO CORPORATION, for $211 million (23.2 billion yen)

13 Nov 2017

BRIEF-Upsher-Smith says parent co to manufacture migraine medication in Japan With AstraZeneca

* Upsher-Smith Laboratories says co's parent Sawai Pharmaceutical entered agreement with AstraZeneca to manufacture & market migraine medication in Japan​

30 Oct 2017

REFILE-TABLE-Sawai Pharmaceutical-Q1 group results

(Adds company forecast. Accounting policy for forecast is IFRS) Aug 14 (Reuters)- Sawai Pharmaceutical Co Ltd CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 3 months ended 3 months ended Year to Jun 30, 2017 Jun 30, 2016 Mar 31, 2018 LATEST YEAR-AGO LATEST RESULTS RESULTS FORECAST Sales 33.65 32.95 

14 Aug 2017

Earnings vs. Estimates